J Eur Acad Dermatol Venereol. 2021 Jul 26. doi: 10.1111/jdv.17533. Online ahead of print.
ABSTRACT
Therapeutic options for patients with metastatic melanoma have greatly improved with the introduction of immune checkpoint-inhibition (ICI) and targeted therapies (TT).(1-4) However, a substantial proportion of patients does not respond or experiences toxicities. Thus, prognostic and predictive biomarkers including metabolic host factors are needed. The modified Glasgow-prognostic-score (mGPS) is a well-established immuno-nutritional prognostic assessment in various cancers(5-8), but not yet assessed in melanoma.
PMID:34310762 | DOI:10.1111/jdv.17533
